Company: BLNE
Filing Date: 2025-03-10
Form Type: 424B7
Source: 0001493152-25-009637
Chunk: 12

Company: Beeline Holdings, Inc.
Filing Date: 2025-03-10
Form: 424B7
Chunk 12
---
 in the Purchase Agreement, including restrictions on when we may sell shares to C/M, restrictions on the amounts we may sell to C/M at any one time, and a limitation on our ability to sell shares to C/M to the extent that it would cause C/M to beneficially own more than 4.99% of our outstanding common stock. In addition, any amounts we sell under the Purchase Agreement may not satisfy all of our funding needs, even if we are able and choose to sell all $10,000,000 under the Purchase Agreement. The sale of the full $10,000,000 could also be further delayed by our need to file a subsequent registration statement on Form S-1 and have such registration statement to be declared effective by the SEC in order to make further sales beyond the $1,500,000 being offered hereby. If we elect to issue and sell more than the shares offered under this prospectus supplement to C/M, which we have the right, but not the obligation, to do, we must first register for resale under the Securities Act any such additional shares.

| S-16 |

We elected to enter into the Purchase Agreement with C/M as a means to access capital quickly as market conditions permit. The extent we rely on C/M as a source of funding will depend on a number of factors including, the prevailing market price and trading volume of our common stock and the extent to which we are able to secure working capital from other sources including an at-the-market offering. We recently executed an engagement letter with a broker-dealer which will be or exclusive sales agent under an at-the-market offering. Subject to their due diligence and customary conditions, we expect in a definitive At-the Market Offering Agreement on or about March 13, 2025. We cannot assure you we will receive any proceeds from the at-the-market offering. Further, the two concurrent offerings may result in us using the at-the-market offering since it will entail a 3% commission. If obtaining sufficient funding from C/M were to prove unavailable or prohibitively dilutive, we will need to secure another source of funding in order to satisfy our working capital needs. Even if we sell the maximum amount of $10 million of shares of common stock to C/M under the Purchase Agreement, we may still need additional capital to fully implement our business, operating and development plans. Should the financing we require to sustain our working capital needs be unavailable or prohibitively expensive when we require it or expose us to substantial restrictive covenants or limitations, the consequences could